| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 1.58e-21 | 14 | 46 | 9 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 6.34e-19 | 23 | 46 | 9 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 7.69e-18 | 29 | 46 | 9 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 7.69e-18 | 29 | 46 | 9 | GO:0035325 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 3.99e-17 | 34 | 46 | 9 | GO:0015125 | |
| GeneOntologyMolecularFunction | glycolipid binding | 1.53e-15 | 49 | 46 | 9 | GO:0051861 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | CEACAM6 PSG8 KL ERN1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 ARF4 | 3.67e-15 | 173 | 46 | 12 | GO:0070851 |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 4.66e-14 | 70 | 46 | 9 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 6.92e-14 | 73 | 46 | 9 | GO:0170055 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 4.90e-13 | 90 | 46 | 9 | GO:0008028 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 1.28e-12 | 149 | 46 | 10 | GO:1990782 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 3.91e-11 | 210 | 46 | 10 | GO:0019903 | |
| GeneOntologyMolecularFunction | calmodulin binding | 9.59e-11 | 230 | 46 | 10 | GO:0005516 | |
| GeneOntologyMolecularFunction | phosphatase binding | 3.69e-10 | 264 | 46 | 10 | GO:0019902 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 5.67e-10 | 196 | 46 | 9 | GO:0005319 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 9.18e-10 | 207 | 46 | 9 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 9.58e-10 | 208 | 46 | 9 | GO:0005342 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 1.02e-09 | 293 | 46 | 10 | GO:0008514 | |
| GeneOntologyMolecularFunction | protein heterodimerization activity | 1.90e-08 | 398 | 46 | 10 | GO:0046982 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 3.66e-08 | 316 | 46 | 9 | GO:0035091 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 4.54e-08 | 324 | 46 | 9 | GO:0005126 | |
| GeneOntologyMolecularFunction | transporter activity | LRRC8A CACNA1C CEACAM6 TPTE PSG8 IGF1R PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 SLC47A2 CALHM2 | 9.92e-08 | 1289 | 46 | 15 | GO:0005215 |
| GeneOntologyMolecularFunction | protein homodimerization activity | CEACAM6 PSG8 CARNMT1 TENM4 ERN1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 2.13e-07 | 815 | 46 | 12 | GO:0042803 |
| GeneOntologyMolecularFunction | transmembrane transporter activity | LRRC8A CACNA1C CEACAM6 TPTE PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 SLC47A2 CALHM2 | 2.36e-07 | 1180 | 46 | 14 | GO:0022857 |
| GeneOntologyMolecularFunction | actin binding | 1.22e-06 | 479 | 46 | 9 | GO:0003779 | |
| GeneOntologyMolecularFunction | phospholipid binding | 3.68e-06 | 548 | 46 | 9 | GO:0005543 | |
| GeneOntologyMolecularFunction | protein dimerization activity | CEACAM6 PSG8 CARNMT1 TENM4 ERN1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 1.26e-05 | 1205 | 46 | 12 | GO:0046983 |
| GeneOntologyMolecularFunction | protein kinase binding | 2.36e-05 | 873 | 46 | 10 | GO:0019901 | |
| GeneOntologyMolecularFunction | kinase binding | 5.72e-05 | 969 | 46 | 10 | GO:0019900 | |
| GeneOntologyMolecularFunction | lipid binding | 6.73e-05 | 988 | 46 | 10 | GO:0008289 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 1.62e-04 | 1099 | 46 | 10 | GO:0008092 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 1.79e-21 | 14 | 48 | 9 | GO:0070348 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 4.47e-21 | 15 | 48 | 9 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 4.47e-21 | 15 | 48 | 9 | GO:0002859 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 4.47e-21 | 15 | 48 | 9 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 4.47e-21 | 15 | 48 | 9 | GO:1903387 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 1.02e-20 | 16 | 48 | 9 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 2.16e-20 | 17 | 48 | 9 | GO:0070342 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 2.16e-20 | 17 | 48 | 9 | GO:0038158 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 2.16e-20 | 17 | 48 | 9 | GO:1901143 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 4.32e-20 | 18 | 48 | 9 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.49e-19 | 20 | 48 | 9 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 2.60e-19 | 21 | 48 | 9 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 2.60e-19 | 21 | 48 | 9 | GO:0002838 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 2.60e-19 | 21 | 48 | 9 | GO:0070345 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 3.00e-19 | 35 | 48 | 10 | GO:1901142 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 4.39e-19 | 22 | 48 | 9 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 7.20e-19 | 23 | 48 | 9 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 7.20e-19 | 23 | 48 | 9 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 1.15e-18 | 24 | 48 | 9 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 1.15e-18 | 24 | 48 | 9 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 1.15e-18 | 24 | 48 | 9 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 1.79e-18 | 25 | 48 | 9 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 1.79e-18 | 25 | 48 | 9 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 4.10e-18 | 27 | 48 | 9 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 6.03e-18 | 28 | 48 | 9 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 8.73e-18 | 29 | 48 | 9 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 1.75e-17 | 31 | 48 | 9 | GO:0010544 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 2.43e-17 | 32 | 48 | 9 | GO:0060312 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 2.43e-17 | 32 | 48 | 9 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 2.43e-17 | 32 | 48 | 9 | GO:0070341 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 3.34e-17 | 33 | 48 | 9 | GO:2000252 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 3.34e-17 | 33 | 48 | 9 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 4.54e-17 | 34 | 48 | 9 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 4.54e-17 | 34 | 48 | 9 | GO:0046851 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 1.40e-16 | 38 | 48 | 9 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 1.82e-16 | 39 | 48 | 9 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.34e-16 | 40 | 48 | 9 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.99e-16 | 41 | 48 | 9 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 3.80e-16 | 42 | 48 | 9 | GO:0090330 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 6.12e-16 | 70 | 48 | 10 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 7.52e-16 | 45 | 48 | 9 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 9.33e-16 | 46 | 48 | 9 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 9.33e-16 | 46 | 48 | 9 | GO:0072574 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 1.15e-15 | 47 | 48 | 9 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 1.15e-15 | 47 | 48 | 9 | GO:0001911 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 1.15e-15 | 47 | 48 | 9 | GO:0034104 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 1.73e-15 | 49 | 48 | 9 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 1.73e-15 | 49 | 48 | 9 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 2.11e-15 | 50 | 48 | 9 | GO:0002834 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 2.50e-15 | 80 | 48 | 10 | GO:0046850 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 3.08e-15 | 52 | 48 | 9 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 3.71e-15 | 53 | 48 | 9 | GO:0034110 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 6.31e-15 | 56 | 48 | 9 | GO:0002418 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 1.04e-14 | 59 | 48 | 9 | GO:0045671 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 1.22e-14 | 60 | 48 | 9 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 1.22e-14 | 60 | 48 | 9 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 1.43e-14 | 61 | 48 | 9 | GO:0060259 | |
| GeneOntologyBiologicalProcess | bone resorption | 2.29e-14 | 99 | 48 | 10 | GO:0045453 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 3.03e-14 | 66 | 48 | 9 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 3.49e-14 | 67 | 48 | 9 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 4.62e-14 | 69 | 48 | 9 | GO:0030195 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 5.29e-14 | 70 | 48 | 9 | GO:1900047 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 6.05e-14 | 71 | 48 | 9 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 6.05e-14 | 71 | 48 | 9 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 6.90e-14 | 72 | 48 | 9 | GO:0032692 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 6.90e-14 | 72 | 48 | 9 | GO:0050819 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 7.85e-14 | 73 | 48 | 9 | GO:0042304 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 1.15e-13 | 76 | 48 | 9 | GO:0042269 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 1.85e-13 | 80 | 48 | 9 | GO:0002715 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 2.61e-13 | 83 | 48 | 9 | GO:0002707 | |
| GeneOntologyBiologicalProcess | bone remodeling | 2.93e-13 | 127 | 48 | 10 | GO:0046849 | |
| GeneOntologyBiologicalProcess | regulation of tissue remodeling | 3.18e-13 | 128 | 48 | 10 | GO:0034103 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 3.26e-13 | 85 | 48 | 9 | GO:1903670 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 3.26e-13 | 85 | 48 | 9 | GO:0002762 | |
| GeneOntologyBiologicalProcess | positive regulation of MAP kinase activity | 3.44e-13 | 129 | 48 | 10 | GO:0043406 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 3.64e-13 | 86 | 48 | 9 | GO:0042058 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 4.05e-13 | 87 | 48 | 9 | GO:0001974 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 6.15e-13 | 91 | 48 | 9 | GO:0051055 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 6.15e-13 | 91 | 48 | 9 | GO:0030193 | |
| GeneOntologyBiologicalProcess | epidermal growth factor receptor signaling pathway | 7.32e-13 | 139 | 48 | 10 | GO:0007173 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 7.52e-13 | 93 | 48 | 9 | GO:1900046 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 7.52e-13 | 93 | 48 | 9 | GO:1901184 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 9.16e-13 | 95 | 48 | 9 | GO:0070527 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 1.01e-12 | 96 | 48 | 9 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 1.01e-12 | 96 | 48 | 9 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 1.22e-12 | 98 | 48 | 9 | GO:0061045 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 2.30e-12 | 105 | 48 | 9 | GO:0042267 | |
| GeneOntologyBiologicalProcess | platelet activation | 2.66e-12 | 158 | 48 | 10 | GO:0030168 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 2.74e-12 | 107 | 48 | 9 | GO:0042130 | |
| GeneOntologyBiologicalProcess | ERBB signaling pathway | 3.02e-12 | 160 | 48 | 10 | GO:0038127 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 3.24e-12 | 109 | 48 | 9 | GO:0002228 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 4.89e-12 | 114 | 48 | 9 | GO:0045824 | |
| GeneOntologyBiologicalProcess | regulation of osteoclast differentiation | 5.73e-12 | 116 | 48 | 9 | GO:0045670 | |
| GeneOntologyBiologicalProcess | vasculogenesis | 6.70e-12 | 118 | 48 | 9 | GO:0001570 | |
| GeneOntologyBiologicalProcess | gland morphogenesis | 8.75e-12 | 178 | 48 | 10 | GO:0022612 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte proliferation | 1.05e-11 | 124 | 48 | 9 | GO:0050672 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 1.05e-11 | 124 | 48 | 9 | GO:0001910 | |
| GeneOntologyBiologicalProcess | homotypic cell-cell adhesion | 1.05e-11 | 124 | 48 | 9 | GO:0034109 | |
| GeneOntologyBiologicalProcess | negative regulation of response to wounding | 1.22e-11 | 126 | 48 | 9 | GO:1903035 | |
| GeneOntologyBiologicalProcess | negative regulation of mononuclear cell proliferation | 1.22e-11 | 126 | 48 | 9 | GO:0032945 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 9.04e-21 | 16 | 48 | 9 | GO:0070021 | |
| GeneOntologyCellularComponent | protein kinase complex | 1.29e-13 | 170 | 48 | 11 | GO:1902911 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 4.93e-13 | 90 | 48 | 9 | GO:0016328 | |
| GeneOntologyCellularComponent | ciliary membrane | 1.08e-12 | 98 | 48 | 9 | GO:0060170 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 2.19e-12 | 157 | 48 | 10 | GO:1902554 | |
| GeneOntologyCellularComponent | T cell receptor complex | 3.19e-12 | 163 | 48 | 10 | GO:0042101 | |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 2.02e-10 | 335 | 48 | 11 | GO:0061695 | |
| GeneOntologyCellularComponent | plasma membrane signaling receptor complex | CEACAM6 PSG8 IGF1R TRBV11-2 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 3.22e-10 | 350 | 48 | 11 | GO:0098802 |
| GeneOntologyCellularComponent | adherens junction | 1.14e-09 | 212 | 48 | 9 | GO:0005912 | |
| GeneOntologyCellularComponent | apical plasma membrane | 1.02e-08 | 487 | 48 | 11 | GO:0016324 | |
| GeneOntologyCellularComponent | cell projection membrane | 4.06e-08 | 431 | 48 | 10 | GO:0031253 | |
| GeneOntologyCellularComponent | basolateral plasma membrane | 4.10e-08 | 320 | 48 | 9 | GO:0016323 | |
| GeneOntologyCellularComponent | receptor complex | CEACAM6 PSG8 IGF1R TRBV11-2 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 6.18e-08 | 581 | 48 | 11 | GO:0043235 |
| GeneOntologyCellularComponent | apical part of cell | 7.48e-08 | 592 | 48 | 11 | GO:0045177 | |
| GeneOntologyCellularComponent | basal plasma membrane | 9.70e-08 | 354 | 48 | 9 | GO:0009925 | |
| GeneOntologyCellularComponent | plasma membrane protein complex | CACNA1C CEACAM6 PSG8 IGF1R TRBV11-2 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 1.45e-07 | 785 | 48 | 12 | GO:0098797 |
| GeneOntologyCellularComponent | basal part of cell | 1.69e-07 | 378 | 48 | 9 | GO:0045178 | |
| GeneOntologyCellularComponent | membrane protein complex | LRRC8A CACNA1C CEACAM6 PSG8 IGF1R ERN1 TRBV11-2 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 UEVLD | 7.19e-07 | 1498 | 48 | 15 | GO:0098796 |
| GeneOntologyCellularComponent | external side of plasma membrane | 2.37e-06 | 519 | 48 | 9 | GO:0009897 | |
| GeneOntologyCellularComponent | cilium | CEACAM6 PSG8 CFAP70 PSG1 WDR11 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 4.54e-06 | 898 | 48 | 11 | GO:0005929 |
| GeneOntologyCellularComponent | cell surface | LRRC8A CACNA1C CEACAM6 PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG7 PSG11 | 5.62e-06 | 1111 | 48 | 12 | GO:0009986 |
| GeneOntologyCellularComponent | cell-cell junction | 6.81e-06 | 591 | 48 | 9 | GO:0005911 | |
| GeneOntologyCellularComponent | transferase complex | 8.82e-06 | 963 | 48 | 11 | GO:1990234 | |
| GeneOntologyCellularComponent | side of membrane | 1.46e-04 | 875 | 48 | 9 | GO:0098552 | |
| GeneOntologyCellularComponent | anchoring junction | 3.29e-04 | 976 | 48 | 9 | GO:0070161 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 6.97e-20 | 17 | 38 | 9 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 8.36e-19 | 21 | 38 | 9 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 3.70e-18 | 24 | 38 | 9 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 1.32e-17 | 27 | 38 | 9 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 1.94e-17 | 28 | 38 | 9 | MP:0020950 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 5.63e-17 | 31 | 38 | 9 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 5.63e-17 | 31 | 38 | 9 | MP:0008964 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 1.96e-16 | 35 | 38 | 9 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 2.60e-16 | 36 | 38 | 9 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 5.83e-16 | 39 | 38 | 9 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 1.93e-15 | 44 | 38 | 9 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 3.69e-15 | 47 | 38 | 9 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 5.55e-15 | 49 | 38 | 9 | MP:0020948 | |
| MousePheno | decreased cellular glucose uptake | 1.19e-14 | 53 | 38 | 9 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 1.42e-14 | 54 | 38 | 9 | MP:0010953 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 3.91e-14 | 60 | 38 | 9 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 4.58e-14 | 61 | 38 | 9 | MP:0010951 | |
| MousePheno | increased insulin secretion | 7.23e-14 | 64 | 38 | 9 | MP:0003058 | |
| MousePheno | abnormal muscle cell glucose uptake | 1.12e-13 | 67 | 38 | 9 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 1.12e-13 | 67 | 38 | 9 | MP:0008962 | |
| MousePheno | abnormal vascular wound healing | 2.51e-13 | 73 | 38 | 9 | MP:0004883 | |
| MousePheno | obese | 3.11e-13 | 113 | 38 | 10 | MP:0001261 | |
| MousePheno | decreased oxygen consumption | 5.25e-13 | 79 | 38 | 9 | MP:0005290 | |
| MousePheno | polyphagia | 5.91e-13 | 80 | 38 | 9 | MP:0001433 | |
| MousePheno | decreased susceptibility to Riboviria infection | 7.44e-13 | 82 | 38 | 9 | MP:0020914 | |
| MousePheno | abnormal cellular glucose uptake | 5.60e-12 | 102 | 38 | 9 | MP:0003925 | |
| MousePheno | decreased respiratory quotient | 1.12e-11 | 110 | 38 | 9 | MP:0010379 | |
| MousePheno | abnormal insulin secretion | 2.03e-11 | 171 | 38 | 10 | MP:0003564 | |
| MousePheno | decreased energy expenditure | 2.29e-11 | 119 | 38 | 9 | MP:0004890 | |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 2.47e-11 | 120 | 38 | 9 | MP:0009786 | |
| MousePheno | abnormal endocrine pancreas secretion | 2.70e-11 | 176 | 38 | 10 | MP:0014195 | |
| MousePheno | increased circulating leptin level | 3.58e-11 | 125 | 38 | 9 | MP:0005669 | |
| MousePheno | decreased susceptibility to viral infection | 3.58e-11 | 125 | 38 | 9 | MP:0002410 | |
| MousePheno | abnormal pancreas secretion | 3.98e-11 | 183 | 38 | 10 | MP:0002694 | |
| MousePheno | abnormal pancreatic beta cell physiology | 7.84e-11 | 196 | 38 | 10 | MP:0003562 | |
| MousePheno | decreased circulating triglyceride level | AHSG CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 1.05e-10 | 275 | 38 | 11 | MP:0002644 |
| MousePheno | abnormal endocrine pancreas physiology | 1.06e-10 | 202 | 38 | 10 | MP:0010147 | |
| MousePheno | increased incidence of tumors by chemical induction | 1.06e-10 | 141 | 38 | 9 | MP:0004499 | |
| MousePheno | abnormal glycogen homeostasis | 1.28e-10 | 144 | 38 | 9 | MP:0005438 | |
| MousePheno | abnormal colon morphology | 2.09e-10 | 152 | 38 | 9 | MP:0000495 | |
| MousePheno | increased incidence of induced tumors | 6.62e-10 | 173 | 38 | 9 | MP:0002021 | |
| MousePheno | abnormal respiratory quotient | 8.53e-10 | 178 | 38 | 9 | MP:0004129 | |
| MousePheno | abnormal susceptibility to Riboviria infection | 1.26e-09 | 186 | 38 | 9 | MP:0020912 | |
| MousePheno | decreased triglyceride level | AHSG CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 1.28e-09 | 348 | 38 | 11 | MP:0005318 |
| MousePheno | increased food intake | 1.45e-09 | 189 | 38 | 9 | MP:0011939 | |
| MousePheno | abnormal wound healing | 1.74e-09 | 193 | 38 | 9 | MP:0005023 | |
| MousePheno | abnormal oxygen consumption | 1.91e-09 | 195 | 38 | 9 | MP:0005288 | |
| MousePheno | abnormal endocrine gland physiology | 2.00e-09 | 363 | 38 | 11 | MP:0013561 | |
| MousePheno | insulin resistance | 2.09e-09 | 197 | 38 | 9 | MP:0005331 | |
| MousePheno | increased physiological sensitivity to xenobiotic | 3.13e-09 | 286 | 38 | 10 | MP:0008873 | |
| MousePheno | abnormal pancreas physiology | 3.82e-09 | 292 | 38 | 10 | MP:0002693 | |
| MousePheno | abnormal energy expenditure | 7.44e-09 | 313 | 38 | 10 | MP:0005450 | |
| MousePheno | abnormal energy homeostasis | 9.76e-09 | 322 | 38 | 10 | MP:0005448 | |
| MousePheno | abnormal circulating leptin level | 1.02e-08 | 236 | 38 | 9 | MP:0005667 | |
| MousePheno | decreased susceptibility to infection | 2.00e-08 | 255 | 38 | 9 | MP:0002409 | |
| MousePheno | abnormal abdominal fat pad morphology | 2.52e-08 | 262 | 38 | 9 | MP:0000010 | |
| MousePheno | increased total tissue mass | 3.13e-08 | 364 | 38 | 10 | MP:0012323 | |
| MousePheno | increased body weight | 3.13e-08 | 364 | 38 | 10 | MP:0001260 | |
| MousePheno | abnormal incidence of induced tumors | 3.17e-08 | 269 | 38 | 9 | MP:0013151 | |
| MousePheno | abnormal large intestine morphology | 3.95e-08 | 276 | 38 | 9 | MP:0000489 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 4.34e-08 | 279 | 38 | 9 | MP:0009785 | |
| MousePheno | abnormal susceptibility to viral infection | 4.34e-08 | 279 | 38 | 9 | MP:0020185 | |
| MousePheno | increased circulating insulin level | 4.90e-08 | 283 | 38 | 9 | MP:0002079 | |
| MousePheno | abnormal circulating insulin level | 6.09e-08 | 505 | 38 | 11 | MP:0001560 | |
| MousePheno | abnormal skeletal muscle morphology | 6.47e-08 | 508 | 38 | 11 | MP:0000759 | |
| MousePheno | abnormal blood vessel physiology | 6.59e-08 | 394 | 38 | 10 | MP:0000249 | |
| MousePheno | abnormal circulating triglyceride level | AHSG CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 7.59e-08 | 516 | 38 | 11 | MP:0011969 |
| MousePheno | abnormal vasculature physiology | 8.34e-08 | 404 | 38 | 10 | MP:0031170 | |
| MousePheno | increased body size | 9.36e-08 | 409 | 38 | 10 | MP:0001264 | |
| MousePheno | abnormal fat pad morphology | 1.19e-07 | 314 | 38 | 9 | MP:0005334 | |
| MousePheno | increased circulating hormone level | 2.39e-07 | 578 | 38 | 11 | MP:0014456 | |
| MousePheno | abnormal induced morbidity/mortality | CEACAM6 PSG8 KL EDIL3 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 F8 PSG11 | 3.21e-07 | 737 | 38 | 12 | MP:0001657 |
| MousePheno | increased triglyceride level | 3.30e-07 | 354 | 38 | 9 | MP:0005317 | |
| MousePheno | increased lean body mass | 3.30e-07 | 354 | 38 | 9 | MP:0003960 | |
| MousePheno | abnormal muscle morphology | AHSG LRRC8A CACNA1C CEACAM6 PSG8 KL IGF1R PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 5.51e-07 | 1106 | 38 | 14 | MP:0002108 |
| MousePheno | abnormal glucose tolerance | AHSG CEACAM6 PSG8 KL PSG1 WDR11 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 6.49e-07 | 787 | 38 | 12 | MP:0005291 |
| MousePheno | abnormal triglyceride level | AHSG CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 6.50e-07 | 639 | 38 | 11 | MP:0000187 |
| MousePheno | increased hormone level | 6.70e-07 | 641 | 38 | 11 | MP:0014454 | |
| MousePheno | abnormal intestine morphology | 1.34e-06 | 546 | 38 | 10 | MP:0000477 | |
| MousePheno | abnormal gland physiology | 1.41e-06 | 691 | 38 | 11 | MP:0002164 | |
| MousePheno | increased total body fat amount | 1.49e-06 | 424 | 38 | 9 | MP:0010024 | |
| MousePheno | decreased lipid level | AHSG CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 2.31e-06 | 727 | 38 | 11 | MP:0014461 |
| MousePheno | abnormal lean body mass | CEACAM6 PAPPA PSG8 TENM4 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 3.09e-06 | 749 | 38 | 11 | MP:0003959 |
| MousePheno | abnormal gas homeostasis | 3.13e-06 | 600 | 38 | 10 | MP:0003948 | |
| MousePheno | impaired glucose tolerance | 4.13e-06 | 480 | 38 | 9 | MP:0005293 | |
| MousePheno | abnormal food intake | 4.20e-06 | 481 | 38 | 9 | MP:0005449 | |
| MousePheno | abnormal circulating hormone level | AHSG CEACAM6 PAPPA PSG8 KL PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 4.91e-06 | 954 | 38 | 12 | MP:0005418 |
| MousePheno | abnormal physiological response to xenobiotic | 7.50e-06 | 662 | 38 | 10 | MP:0008872 | |
| MousePheno | abnormal susceptibility to infection | 8.56e-06 | 672 | 38 | 10 | MP:0001793 | |
| MousePheno | increased tumor incidence | 9.22e-06 | 530 | 38 | 9 | MP:0002020 | |
| MousePheno | abnormal response to infection | 1.46e-05 | 714 | 38 | 10 | MP:0005025 | |
| MousePheno | abnormal hormone level | AHSG CEACAM6 PAPPA PSG8 KL PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 1.63e-05 | 1073 | 38 | 12 | MP:0003953 |
| MousePheno | abnormal response to antigen | 1.68e-05 | 726 | 38 | 10 | MP:0020000 | |
| MousePheno | abnormal eating behavior | 2.62e-05 | 604 | 38 | 9 | MP:0001431 | |
| MousePheno | abnormal response to injury | 2.72e-05 | 607 | 38 | 9 | MP:0005164 | |
| MousePheno | abnormal muscle physiology | CACNA1C CEACAM6 PSG8 SH3TC1 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 3.07e-05 | 954 | 38 | 11 | MP:0002106 |
| MousePheno | abnormal tumor incidence | 3.88e-05 | 635 | 38 | 9 | MP:0002019 | |
| MousePheno | abnormal tumor susceptibility | 4.66e-05 | 650 | 38 | 9 | MP:0002166 | |
| MousePheno | increased lipid level | 6.31e-05 | 847 | 38 | 10 | MP:0014460 | |
| MousePheno | abnormal digestive system morphology | CEACAM6 PSG8 KL MMP15 PSG1 WDR11 PSG2 PSG3 PSG4 PSG5 PSG6 PSG11 | 6.51e-05 | 1233 | 38 | 12 | MP:0000462 |
| Domain | Ig_2 | 9.78e-16 | 73 | 44 | 10 | PF13895 | |
| Domain | V-set | 1.25e-11 | 184 | 44 | 10 | PF07686 | |
| Domain | ig | 1.72e-11 | 190 | 44 | 10 | PF00047 | |
| Domain | Immunoglobulin | 1.72e-11 | 190 | 44 | 10 | IPR013151 | |
| Domain | Ig_V-set | 2.72e-11 | 199 | 44 | 10 | IPR013106 | |
| Domain | IGc2 | 1.40e-10 | 235 | 44 | 10 | SM00408 | |
| Domain | Ig_sub2 | 1.40e-10 | 235 | 44 | 10 | IPR003598 | |
| Domain | IG | 3.81e-08 | 421 | 44 | 10 | SM00409 | |
| Domain | Ig_sub | 3.81e-08 | 421 | 44 | 10 | IPR003599 | |
| Domain | IG_LIKE | 1.60e-07 | 491 | 44 | 10 | PS50835 | |
| Domain | Ig-like_dom | 2.00e-07 | 503 | 44 | 10 | IPR007110 | |
| Domain | - | 2.74e-07 | 663 | 44 | 11 | 2.60.40.10 | |
| Domain | Ig-like_fold | 5.11e-07 | 706 | 44 | 11 | IPR013783 | |
| Domain | OLF | 4.16e-04 | 13 | 44 | 2 | PS51132 | |
| Domain | Olfac-like_dom | 4.16e-04 | 13 | 44 | 2 | IPR003112 | |
| Domain | OLF | 4.16e-04 | 13 | 44 | 2 | SM00284 | |
| Domain | OLF | 4.16e-04 | 13 | 44 | 2 | PF02191 | |
| Domain | - | 6.76e-04 | 73 | 44 | 3 | 2.60.120.260 | |
| Domain | FA58C | 1.11e-03 | 21 | 44 | 2 | SM00231 | |
| Domain | FA58C_3 | 1.11e-03 | 21 | 44 | 2 | PS50022 | |
| Domain | FA58C_1 | 1.11e-03 | 21 | 44 | 2 | PS01285 | |
| Domain | FA58C_2 | 1.11e-03 | 21 | 44 | 2 | PS01286 | |
| Domain | Galactose-bd-like | 1.41e-03 | 94 | 44 | 3 | IPR008979 | |
| Domain | F5_F8_type_C | 1.45e-03 | 24 | 44 | 2 | PF00754 | |
| Domain | FA58C | 1.45e-03 | 24 | 44 | 2 | IPR000421 | |
| Domain | hEGF | 1.97e-03 | 28 | 44 | 2 | PF12661 | |
| Domain | ARF | 2.11e-03 | 29 | 44 | 2 | PS51417 | |
| Domain | Small_GTPase_ARF | 2.11e-03 | 29 | 44 | 2 | IPR024156 | |
| Domain | Arf | 2.42e-03 | 31 | 44 | 2 | PF00025 | |
| Domain | Small_GTPase_ARF/SAR | 2.73e-03 | 33 | 44 | 2 | IPR006689 | |
| Domain | - | 3.07e-03 | 35 | 44 | 2 | 3.20.20.80 | |
| Domain | Glyco_hydro_catalytic_dom | 3.61e-03 | 38 | 44 | 2 | IPR013781 | |
| Domain | Glycoside_hydrolase_SF | 6.93e-03 | 53 | 44 | 2 | IPR017853 | |
| Domain | EGF_extracell | 8.80e-03 | 60 | 44 | 2 | IPR013111 | |
| Domain | EGF_2 | 8.80e-03 | 60 | 44 | 2 | PF07974 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | CEACAM6 PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG7 PSG11 IGKV3-20 | 1.58e-12 | 194 | 37 | 11 | M16312 |
| Pathway | REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS | 3.03e-12 | 99 | 37 | 9 | MM14624 | |
| Pathway | WP_EGFR1_SIGNALING_PATHWAY | 3.57e-11 | 188 | 37 | 10 | MM15828 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 2.11e-10 | 158 | 37 | 9 | MM14812 | |
| Pathway | REACTOME_HEMOSTASIS | AHSG CEACAM6 PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG7 F8 PSG11 IGKV3-20 DGKK | 6.90e-10 | 679 | 37 | 14 | M8395 |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 7.99e-10 | 258 | 37 | 10 | MM14572 | |
| Pathway | REACTOME_HEMOSTASIS | AHSG CEACAM6 PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 F8 PSG11 DGKK | 1.27e-08 | 571 | 37 | 12 | MM14472 |
| Pathway | REACTOME_NEUTROPHIL_DEGRANULATION | 4.64e-08 | 511 | 37 | 11 | MM15330 | |
| Pathway | REACTOME_INNATE_IMMUNE_SYSTEM | 3.18e-05 | 995 | 37 | 11 | MM14661 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | AHSG CEACAM6 PSG8 PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 F8 PSG11 ARF4 | 1.42e-04 | 1389 | 37 | 12 | MM15307 |
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 5.83e-24 | 13 | 48 | 9 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 5.83e-24 | 13 | 48 | 9 | 1985902 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 10964771 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 5.83e-24 | 13 | 48 | 9 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 5.83e-24 | 13 | 48 | 9 | 16638824 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 20044046 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 32150576 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 22469976 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 5.83e-24 | 13 | 48 | 9 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 5.83e-24 | 13 | 48 | 9 | 28035001 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 5.83e-24 | 13 | 48 | 9 | 12832451 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 5.83e-24 | 13 | 48 | 9 | 15316023 | |
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 5.83e-24 | 13 | 48 | 9 | 21670291 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 22162753 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 5.83e-24 | 13 | 48 | 9 | 23935487 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 2702644 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 8380065 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 1279194 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 15331748 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 5.83e-24 | 13 | 48 | 9 | 22406619 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 7628460 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 25724769 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 26374765 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 5.83e-24 | 13 | 48 | 9 | 25972571 | |
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 5.83e-24 | 13 | 48 | 9 | 22092845 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 11801635 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 28913658 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 19008452 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 5.83e-24 | 13 | 48 | 9 | 15220458 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 5.83e-24 | 13 | 48 | 9 | 8500759 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 5.83e-24 | 13 | 48 | 9 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 5.83e-24 | 13 | 48 | 9 | 23800882 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 15207636 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 19285068 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 21760897 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 5.83e-24 | 13 | 48 | 9 | 1326665 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 21081647 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 5.83e-24 | 13 | 48 | 9 | 39168268 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 11483763 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 8402684 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 2164599 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 16619040 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 5.83e-24 | 13 | 48 | 9 | 8209741 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 5.83e-24 | 13 | 48 | 9 | 21949477 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 29396368 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 26219866 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 18003729 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 26284027 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 2133556 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 32521208 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 5.83e-24 | 13 | 48 | 9 | 33352461 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 19406938 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 38381498 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 20739537 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 5.83e-24 | 13 | 48 | 9 | 29967450 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 5.83e-24 | 13 | 48 | 9 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 5.83e-24 | 13 | 48 | 9 | 27695943 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 20404914 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 16680193 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 26911181 | ||
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 1653760 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 5.83e-24 | 13 | 48 | 9 | 32027621 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 5.83e-24 | 13 | 48 | 9 | 27777319 | |
| Pubmed | 5.83e-24 | 13 | 48 | 9 | 18848945 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 37531413 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 23780386 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 28567513 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 8207827 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 1.63e-23 | 14 | 48 | 9 | 34666041 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 19700760 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 34619794 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 1.63e-23 | 14 | 48 | 9 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 1.63e-23 | 14 | 48 | 9 | 29746166 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 9212243 | ||
| Pubmed | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. | 1.63e-23 | 14 | 48 | 9 | 27572314 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 1648219 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 1.63e-23 | 14 | 48 | 9 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 1.63e-23 | 14 | 48 | 9 | 32209360 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 11994468 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 11850617 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 1.63e-23 | 14 | 48 | 9 | 27161904 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 1.63e-23 | 14 | 48 | 9 | 26196244 | |
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 8896983 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 22962327 | ||
| Pubmed | 1.63e-23 | 14 | 48 | 9 | 17623671 | ||
| Interaction | PSG4 interactions | 2.76e-12 | 8 | 46 | 5 | int:PSG4 | |
| Interaction | PSG1 interactions | 1.68e-09 | 51 | 46 | 6 | int:PSG1 | |
| Interaction | CEACAM7 interactions | 3.87e-07 | 7 | 46 | 3 | int:CEACAM7 | |
| Interaction | PTK7 interactions | 2.18e-06 | 168 | 46 | 6 | int:PTK7 | |
| Interaction | PSG8 interactions | 2.26e-06 | 41 | 46 | 4 | int:PSG8 | |
| Interaction | NLGN3 interactions | 3.02e-06 | 99 | 46 | 5 | int:NLGN3 | |
| Interaction | PSG3 interactions | 1.66e-05 | 22 | 46 | 3 | int:PSG3 | |
| Interaction | PSG6 interactions | 3.05e-05 | 4 | 46 | 2 | int:PSG6 | |
| Interaction | PSG5 interactions | 5.07e-05 | 5 | 46 | 2 | int:PSG5 | |
| Interaction | SDF2L1 interactions | 8.68e-05 | 322 | 46 | 6 | int:SDF2L1 | |
| Cytoband | 19q13.2 | 1.13e-13 | 164 | 48 | 9 | 19q13.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | 3.58e-07 | 1192 | 48 | 10 | chr19q13 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 2.71e-24 | 11 | 32 | 9 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 7.40e-12 | 163 | 32 | 9 | 590 | |
| GeneFamily | UPF1 like RNA helicases | 1.65e-04 | 11 | 32 | 2 | 1169 | |
| GeneFamily | Ring finger proteins|Tripartite motif containing|ARF GTPase family | 1.37e-03 | 31 | 32 | 2 | 357 | |
| GeneFamily | Immunoglobulin kappa locus at 2p11.2 | 9.45e-03 | 83 | 32 | 2 | 351 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 1.76e-02 | 115 | 32 | 2 | 769 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 2.84e-18 | 32 | 48 | 9 | MM2 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 7.12e-18 | 35 | 48 | 9 | MM757 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 1.66e-16 | 48 | 48 | 9 | MM531 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 1.20e-14 | 75 | 48 | 9 | MM605 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 4.82e-14 | 87 | 48 | 9 | MM851 | |
| Coexpression | HOLLERN_EMT_BREAST_TUMOR_DN | 5.19e-14 | 135 | 48 | 10 | MM965 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 8.97e-14 | 93 | 48 | 9 | M40279 | |
| Coexpression | DESCARTES_FETAL_ADRENAL_CSH1_CSH2_POSITIVE_CELLS | 2.38e-13 | 224 | 48 | 11 | M40145 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP | 1.70e-12 | 128 | 48 | 9 | MM1000 | |
| Coexpression | BROWN_MYELOID_CELL_DEVELOPMENT_UP | 2.85e-12 | 201 | 48 | 10 | MM1006 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_UP | 4.65e-12 | 143 | 48 | 9 | MM989 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 1.21e-11 | 159 | 48 | 9 | MM760 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 4.09e-11 | 182 | 48 | 9 | MM993 | |
| Coexpression | OHGUCHI_LIVER_HNF4A_TARGETS_DN | 9.92e-11 | 201 | 48 | 9 | MM1294 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MYELOID_CELL_AGEING | 2.13e-10 | 219 | 48 | 9 | MM3826 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_3_4WK_UP | 3.29e-10 | 230 | 48 | 9 | MM986 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_4_5WK_UP | 2.10e-09 | 284 | 48 | 9 | MM987 | |
| Coexpression | ZHANG_UTERUS_C1_REGENERATIVE_UP | 3.59e-09 | 302 | 48 | 9 | MM16604 | |
| Coexpression | KOBAYASHI_EGFR_SIGNALING_24HR_UP | 3.22e-08 | 102 | 48 | 6 | M10290 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 8.48e-08 | 436 | 48 | 9 | MM1326 | |
| Coexpression | KUMAR_TARGETS_OF_MLL_AF9_FUSION | 1.41e-07 | 463 | 48 | 9 | MM1011 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP | 2.28e-07 | 490 | 48 | 9 | MM1001 | |
| Coexpression | BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS | 3.76e-07 | 871 | 48 | 11 | MM1005 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_UP | 4.68e-07 | 534 | 48 | 9 | MM1050 | |
| Coexpression | DESCARTES_MAIN_FETAL_TROPHOBLAST_GIANT_CELLS | 6.91e-07 | 171 | 48 | 6 | M40134 | |
| Coexpression | MARTINEZ_RB1_TARGETS_UP | 7.60e-07 | 741 | 48 | 10 | MM1037 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING | 7.82e-07 | 568 | 48 | 9 | MM3824 | |
| Coexpression | MARTINEZ_RB1_AND_TP53_TARGETS_UP | 3.81e-06 | 689 | 48 | 9 | MM1041 | |
| Coexpression | MARTINEZ_TP53_TARGETS_UP | 4.04e-06 | 694 | 48 | 9 | MM1039 | |
| Coexpression | TABULA_MURIS_SENIS_SKIN_BULGE_KERATINOCYTE_AGEING | 5.02e-06 | 915 | 48 | 10 | MM3828 | |
| Coexpression | ZHANG_UTERUS_C7_EPITHELIAL2_CELL | 1.25e-05 | 799 | 48 | 9 | MM16613 | |
| Coexpression | TABULA_MURIS_SENIS_GONADAL_ADIPOSE_TISSUE_ENDOTHELIAL_CELL_AGEING | 2.26e-05 | 1088 | 48 | 10 | MM3699 | |
| Coexpression | MISSIAGLIA_REGULATED_BY_METHYLATION_UP | 8.15e-05 | 125 | 48 | 4 | M12272 | |
| Coexpression | GOZGIT_ESR1_TARGETS_DN | 8.23e-05 | 786 | 48 | 8 | M10961 | |
| Coexpression | FURUKAWA_DUSP6_TARGETS_PCI35_UP | 3.28e-04 | 73 | 48 | 3 | M6998 | |
| Coexpression | DESCARTES_FETAL_LUNG_CSH1_CSH2_POSITIVE_CELLS | 6.23e-04 | 213 | 48 | 4 | M40238 | |
| Coexpression | BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP | 6.98e-04 | 822 | 48 | 7 | M6782 | |
| CoexpressionAtlas | placenta | 3.05e-09 | 349 | 46 | 10 | placenta | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Keratinizing_Cervical_Squamous_Cell_Carcinoma-6|TCGA-Cervix / Sample_Type by Project: Shred V9 | 2.44e-14 | 136 | 48 | 9 | 2c723777fadc5946df67d3e992471d8134b827f4 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW19|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 5.72e-08 | 191 | 48 | 6 | b5328733da3d3d77c4f6fc5e2ba2035f8898f172 | |
| Computational | Neighborhood of EGFR | 4.11e-14 | 32 | 34 | 8 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 9.15e-14 | 35 | 34 | 8 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 4.52e-13 | 42 | 34 | 8 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 9.90e-13 | 46 | 34 | 8 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.70e-12 | 49 | 34 | 8 | GNF2_KISS1 | |
| Computational | Neighborhood of CDKN1C | 1.78e-10 | 27 | 34 | 6 | GNF2_CDKN1C | |
| Drug | AC1L1IPV | 7.24e-19 | 43 | 46 | 10 | CID000004683 | |
| Drug | Rgd Peptide | 3.94e-11 | 239 | 46 | 10 | CID000104802 | |
| Drug | bromodeoxyuridine | 7.75e-07 | 376 | 46 | 8 | CID000006035 | |
| Drug | pP-8 | 9.17e-07 | 10 | 46 | 3 | CID000444681 | |
| Drug | Didemnins | 2.77e-06 | 14 | 46 | 3 | CID000123844 | |
| Drug | NSC-4928 | 5.71e-06 | 58 | 46 | 4 | CID000221086 | |
| Drug | valganciclovir | 1.16e-05 | 22 | 46 | 3 | CID000064147 | |
| Drug | calcium phosphate | 1.24e-05 | 149 | 46 | 5 | CID000024441 | |
| Drug | 16-epiestriol | 1.77e-05 | 77 | 46 | 4 | CID000003269 | |
| Drug | cyanogen-bromide | 4.42e-05 | 34 | 46 | 3 | CID000010476 | |
| Drug | Fenbufen [36330-85-5]; Up 200; 15.8uM; MCF7; HT_HG-U133A | 4.74e-05 | 197 | 46 | 5 | 2308_UP | |
| Disease | cD177 antigen measurement | 2.62e-16 | 18 | 43 | 7 | EFO_0021866 | |
| Disease | pregnancy-specific beta-1-glycoprotein 3 measurement | 1.00e-07 | 7 | 43 | 3 | EFO_0801906 | |
| Disease | level of pregnancy-specific beta-1-glycoprotein 3 in blood serum | 2.07e-06 | 2 | 43 | 2 | OBA_2043058 | |
| Disease | level of pregnancy-specific beta-1-glycoprotein 4 in blood serum | 2.07e-06 | 2 | 43 | 2 | OBA_2043059 | |
| Disease | pregnancy-specific beta-1-glycoprotein 4 measurement | 3.10e-05 | 6 | 43 | 2 | EFO_0801907 | |
| Disease | birth weight | 2.78e-04 | 399 | 43 | 5 | EFO_0004344 | |
| Disease | visual perception measurement | 3.11e-04 | 223 | 43 | 4 | EFO_0009700 | |
| Disease | sorbitol measurement | 5.15e-04 | 23 | 43 | 2 | EFO_0010533 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 8.45e-04 | 291 | 43 | 4 | EFO_0008317, EFO_0020946 | |
| Disease | type 2 diabetes mellitus (is_marker_for) | 1.03e-03 | 136 | 43 | 3 | DOID:9352 (is_marker_for) | |
| Disease | major depressive episode, major depressive disorder | 1.20e-03 | 35 | 43 | 2 | EFO_0007634, MONDO_0002009 | |
| Disease | hypospadias | 1.49e-03 | 39 | 43 | 2 | EFO_0004209 | |
| Disease | aspirin use measurement | 1.49e-03 | 39 | 43 | 2 | EFO_0007013 | |
| Disease | unipolar depression, bipolar disorder | 1.53e-03 | 156 | 43 | 3 | EFO_0003761, MONDO_0004985 | |
| Disease | Calcinosis | 1.72e-03 | 42 | 43 | 2 | C0006663 | |
| Disease | Microcalcification | 1.72e-03 | 42 | 43 | 2 | C0521174 | |
| Disease | Tumoral calcinosis | 1.72e-03 | 42 | 43 | 2 | C0263628 | |
| Disease | free cholesterol to total lipids in IDL percentage | 1.80e-03 | 43 | 43 | 2 | EFO_0022278 | |
| Disease | asthma exacerbation measurement, response to corticosteroid | 2.53e-03 | 51 | 43 | 2 | EFO_0007614, GO_0031960 | |
| Disease | left ventricular diastolic function measurement | 2.83e-03 | 54 | 43 | 2 | EFO_0008204 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YKLYPWIHQFSNNRR | 251 | Q8N4J0 | |
| LYYHWCKPQQKGLRL | 111 | Q6NTF7 | |
| LYNWRYKNLGNLPHV | 1146 | O60306 | |
| QWHTVQLKYYNKPLL | 1451 | Q9HCU4 | |
| LWYNHIAYIPIQIGN | 646 | Q8IWT6 | |
| HPGQYNSRLKNKMWY | 881 | Q5KSL6 | |
| NYWLIQYQRLLNQKP | 546 | Q6UWE0 | |
| HNLPQNRIGYSWYKG | 56 | P40199 | |
| VHAENWLRLYGYLPQ | 51 | P51511 | |
| QGLPLYSRLHKWAQG | 291 | Q9HA72 | |
| ILLHGLKPWTQYAVY | 566 | P08069 | |
| QYGQWAPKLARLHYS | 2061 | P00451 | |
| NAHRSYLPGQWVYLA | 186 | Q13219 | |
| SKQPLWNHLLNYYKE | 891 | Q92900 | |
| PYYARLNKKGLINAW | 191 | O43854 | |
| YGLLFHPNAYLRNGW | 181 | Q13936 | |
| KLNYLRNYWLLIGHH | 351 | O75460 | |
| DYINQNLPWGYKHTL | 46 | P02765 | |
| LNPNVWGLKGHLYFL | 961 | Q5T0N1 | |
| KIYPWLYHNGGNIIS | 166 | Q6UWU2 | |
| LYHWDLPQRLQDAYG | 191 | Q9UEF7 | |
| WYQQKPGQAPRLLIY | 56 | P01619 | |
| WYQQKPGQAPRLLIY | 56 | A0A075B6H7 | |
| WPRSIYHYGNKKQLL | 176 | Q9UK59 | |
| HNLPQNLAGYIWYKG | 56 | Q00888 | |
| HNLPQNLTGYIWYKG | 56 | Q9UQ72 | |
| HNLPQNLTGYIWYKG | 56 | P11464 | |
| HNLPQNLAGYIWYKG | 56 | Q16557 | |
| LYNLLAKYLQNQGWL | 166 | Q86VL8 | |
| PRNYYIQWLNGSLIH | 96 | Q6UX01 | |
| HNLPQNLTGYIWYKG | 56 | Q00889 | |
| HNLPQNLTGYIWYKG | 56 | Q9UQ74 | |
| HAWLQAGKIYYILRQ | 1071 | Q8TE82 | |
| YKWLKQNVQGLYPQS | 346 | Q9BVR0 | |
| HNLPQNLTGYIWYKG | 56 | Q13046 | |
| YNPKDRLLYAWDNGH | 726 | Q68BL8 | |
| RDYSPQHPNKGLYWV | 276 | Q6UX06 | |
| PLWKHYFQNTQGLIF | 76 | P18085 | |
| YFAQVKHLYNWNLPP | 396 | P56180 | |
| LYWYQQILGQGPKLL | 51 | A0A584 | |
| PLWRYSYDLNGNLHL | 2211 | Q6N022 | |
| QGRIYLPYLQNWSHP | 106 | Q8IX04 | |
| PIPYWLYKLHGLNIN | 391 | Q12874 | |
| HNLPQNLTGYIWYKG | 56 | P11465 | |
| LRPLWKHYYLNTQAV | 461 | P36406 | |
| KAFLLHQPWNGQYSL | 856 | Q9BZH6 | |
| HNLPQNLAGYIWYKG | 56 | Q15238 | |
| QPLDNYFRHLWNKAL | 26 | Q9H3S4 |